GBS Inc. (GBS): Price and Financial Metrics

GBS Inc. (GBS): $3.12

-0.14 (-4.29%)

POWR Rating

Component Grades













GBS Stock Price Chart Interactive Chart >

Price chart for GBS

GBS Price/Volume Stats

Current price $3.12 52-week high $14.24
Prev. close $3.26 52-week low $2.44
Day low $3.10 Volume 400,300
Day high $3.28 Avg. volume 650,024
50-day MA $3.27 Dividend yield N/A
200-day MA $0.00 Market Cap 38.63M

GBS Inc. (GBS) Company Bio

GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It operates in Mainland China, Hong Kong, Vietnam, and Bangladesh. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

GBS Latest News Stream

Event/Time News Detail
Loading, please wait...

GBS Latest Social Stream

Loading social stream, please wait...

View Full GBS Social Stream

Latest GBS News From Around the Web

Below are the latest news stories about GBS Inc that investors may wish to consider to help them evaluate GBS as an investment opportunity.

GBS Inc. to Present at Upcoming September Virtual Investor Conferences

H.C. Wainwright 23 rd Global Investor Conference: September 13 th - 15 th

Intrado Digital Media | September 7, 2021

GBS Inc. to Present at Upcoming September Virtual Investor Conferences

H.C. Wainwright 23rd Global Investor Conference: September 13th - 15th Benzinga Healthcare Small Cap Conference: September 29th - 30th NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced its participation in the following investor conferences in the month of September and invites investors to join virtually. H.C. Wainwrigh

Yahoo | September 7, 2021

21 Stocks Moving in Wednesday's Pre-Market Session

Gainers GBS Inc. (NASDAQ: GBS) rose 72.3% to $5.58 in pre-market trading. The company markets saliva test for diabetes management and previously announced collaboration on covid-19 diagnostic with Harvard's Wyss Institute. Field Trip Health Ltd. (NASDAQ: FTRP) shares rose 30% to $6.25 in pre-market trading. HC Wainwright & Co. initiated coverage on Field Trip Health with a Buy rating and announced a price target of $20. Focus Universal Inc. (NASDAQ: FCUV) rose 25.1% to $6.38 in pre-market tradin

Yahoo | September 1, 2021

Point of Care Testing Company GBS Develops Technology to Take the Fear out of Diabetes and COVID Testing

GBS Inc. is presenting at the Benzinga Healthcare Small Cap Conference on September 29, 2021. For some people with diabetes, testing with a pinprick is no more than a minor inconvenience. But for many adults with testing phobias, they not only face the possibility of a rapid heartbeat or even passing out but could also skip much-needed glucose testing, putting their lives at risk. GBS Inc. (NASDAQ: GBS) understands that testing anxiety can be a life-or-death dilemma and is on a mission to develo

Yahoo | August 17, 2021

GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights

- Awarded $4.7 Million Government Grant Funding to support the building of a high-tech manufacturing facility -

Intrado Digital Media | August 11, 2021

Read More 'GBS' Stories Here

GBS Price Returns

1-mo 7.59%
3-mo -16.80%
6-mo -51.78%
1-year N/A
3-year N/A
5-year N/A
YTD -57.84%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7202 seconds.